[10,13-dimethyl-17-(6-methylhept-5-en-2-yl)-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [10,13-dimethyl-17-(6-methylhept-5-en-2-yl)-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
• 化学式: C₂₇H₄₂O₄S
• 分子量: 462.7
• InChiKey: KUXGXOHYYLSZCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：US20190029984A1

  公开（公告）日：2019-01-31

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
• TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Rgenix, Inc.

  公开号：US20190125745A1

  公开（公告）日：2019-05-02

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• [EN] TREATMENT AND DIAGNOSIS OF CANCER<br/>[FR] TRAITEMENT ET DIAGNOSTIC DU CANCER
  申请人：RGENIX INC

  公开号：WO2016100619A2

  公开（公告）日：2016-06-23

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• [EN] METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS<br/>[FR] MÉTHODES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À DES CELLULES SUPPRESSIVES DÉRIVÉES DE CELLULES MYÉLOÏDES
  申请人：UNIV ROCKEFELLER

  公开号：WO2017123568A2

  公开（公告）日：2017-07-20

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.